Birdwatch Note
2024-08-13 22:35:42 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
The scholarly articles have report "...These results suggest that a third dose of BNT162b2 is safe, improves humoral immunity against SARS-CoV-2, and could be immunologically beneficial for cancer patients on active chemotherapy." : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004706/ A scientific study is needed NOT speculation
Written by 10739CC00539BAF38A77168091145CABF704880D9ABA02D7F1A41D6589471049
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1823356443824672771
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1823488630217957579
- noteId - 1823488630217957579
- participantId -
- noteAuthorParticipantId - 10739CC00539BAF38A77168091145CABF704880D9ABA02D7F1A41D6589471049 Participant Details
- createdAtMillis - 1723588542881
- tweetId - 1823356443824672771
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- The scholarly articles have report "...These results suggest that a third dose of BNT162b2 is safe, improves humoral immunity against SARS-CoV-2, and could be immunologically beneficial for cancer patients on active chemotherapy." : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004706/ A scientific study is needed NOT speculation
Note Ratings
| rated at | rated by | |
| 2024-08-16 13:10:56 -0500 | Rating Details | |
| 2024-08-16 12:44:11 -0500 | Rating Details | |
| 2024-08-15 01:47:07 -0500 | Rating Details | |
| 2024-08-14 22:36:46 -0500 | Rating Details | |
| 2024-08-14 18:54:06 -0500 | Rating Details | |
| 2024-08-14 16:30:42 -0500 | Rating Details | |
| 2024-08-14 12:54:55 -0500 | Rating Details | |
| 2024-08-14 12:38:56 -0500 | Rating Details | |
| 2024-08-14 12:33:28 -0500 | Rating Details | |
| 2024-08-14 11:48:52 -0500 | Rating Details | |
| 2024-08-14 08:14:47 -0500 | Rating Details | |
| 2024-08-14 07:50:29 -0500 | Rating Details | |
| 2024-08-14 07:46:47 -0500 | Rating Details | |
| 2024-08-14 07:28:39 -0500 | Rating Details | |
| 2024-08-14 07:02:11 -0500 | Rating Details | |
| 2024-08-14 06:55:02 -0500 | Rating Details | |
| 2024-08-14 06:43:57 -0500 | Rating Details | |
| 2024-08-14 06:06:27 -0500 | Rating Details | |
| 2024-08-14 05:26:52 -0500 | Rating Details | |
| 2024-08-14 05:17:38 -0500 | Rating Details | |
| 2024-08-14 05:07:43 -0500 | Rating Details | |
| 2024-08-14 04:24:20 -0500 | Rating Details | |
| 2024-08-14 03:33:47 -0500 | Rating Details | |
| 2024-08-14 03:22:32 -0500 | Rating Details | |
| 2024-08-14 03:18:12 -0500 | Rating Details | |
| 2024-08-14 03:13:12 -0500 | Rating Details | |
| 2024-08-14 02:46:23 -0500 | Rating Details | |
| 2024-08-14 02:33:32 -0500 | Rating Details | |
| 2024-08-14 02:31:16 -0500 | Rating Details | |
| 2024-08-14 02:24:21 -0500 | Rating Details | |
| 2024-08-14 02:09:58 -0500 | Rating Details | |
| 2024-08-14 01:36:49 -0500 | Rating Details | |
| 2024-08-14 01:00:30 -0500 | Rating Details | |
| 2024-08-14 00:50:20 -0500 | Rating Details | |
| 2024-08-14 00:26:07 -0500 | Rating Details | |
| 2024-08-14 00:13:25 -0500 | Rating Details | |
| 2024-08-13 23:53:35 -0500 | Rating Details | |
| 2024-08-13 23:49:01 -0500 | Rating Details | |
| 2024-08-13 23:46:22 -0500 | Rating Details | |
| 2024-08-13 23:30:01 -0500 | Rating Details | |
| 2024-08-13 23:15:02 -0500 | Rating Details | |
| 2024-08-13 23:11:45 -0500 | Rating Details | |
| 2024-08-13 23:08:05 -0500 | Rating Details | |
| 2024-08-13 22:24:47 -0500 | Rating Details | |
| 2024-08-13 22:23:04 -0500 | Rating Details | |
| 2024-08-13 22:09:11 -0500 | Rating Details | |
| 2024-08-13 21:20:51 -0500 | Rating Details | |
| 2024-08-13 21:06:35 -0500 | Rating Details | |
| 2024-08-13 20:49:20 -0500 | Rating Details | |
| 2024-08-13 20:37:01 -0500 | Rating Details | |
| 2024-08-13 20:14:58 -0500 | Rating Details | |
| 2024-08-13 19:39:09 -0500 | Rating Details | |
| 2024-08-13 19:36:08 -0500 | Rating Details | |
| 2024-08-13 19:21:30 -0500 | Rating Details | |
| 2024-08-13 19:08:04 -0500 | Rating Details | |
| 2024-08-13 18:31:43 -0500 | Rating Details | |
| 2024-08-13 18:27:44 -0500 | Rating Details | |
| 2024-08-13 18:26:54 -0500 | Rating Details | |
| 2024-08-13 18:09:35 -0500 | Rating Details | |
| 2024-08-13 17:57:37 -0500 | Rating Details | |
| 2024-08-13 17:57:22 -0500 | Rating Details | |
| 2024-08-13 17:56:49 -0500 | Rating Details | |
| 2024-08-13 17:51:22 -0500 | Rating Details | |
| 2024-08-20 11:15:05 -0500 | Rating Details | |
| 2024-08-14 08:35:20 -0500 | Rating Details | |
| 2024-08-14 06:12:56 -0500 | Rating Details | |
| 2024-08-14 05:56:48 -0500 | Rating Details | |
| 2024-08-14 04:51:00 -0500 | Rating Details | |
| 2024-08-14 04:43:29 -0500 | Rating Details | |
| 2024-08-14 02:48:43 -0500 | Rating Details | |
| 2024-08-14 02:23:45 -0500 | Rating Details | |
| 2024-08-14 01:47:33 -0500 | Rating Details | |
| 2024-08-14 00:25:13 -0500 | Rating Details | |
| 2024-08-13 22:42:24 -0500 | Rating Details | |
| 2024-08-13 21:37:17 -0500 | Rating Details | |
| 2024-08-13 21:26:08 -0500 | Rating Details | |
| 2024-08-13 21:15:14 -0500 | Rating Details | |
| 2024-08-13 18:27:26 -0500 | Rating Details | |
| 2024-08-13 18:02:41 -0500 | Rating Details |